Comparing RPH-030 to Vectibix for metastatic colorectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether a new drug called RPH-030 works similarly to an existing drug called Vectibix in treating advanced colorectal cancer that has spread. Both drugs will be given alongside chemotherapy (FOLFIRI) as a first-line treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have metastatic colorectal cancer (cancer that has spread) confirmed by biopsy, and it is your first time receiving systemic cancer treatment
- Your cancer has wild-type RAS (a genetic marker that makes you eligible for this type of treatment)
- You have good overall health (ECOG performance status 0–1, meaning you can do most daily activities)
- You have at least one measurable tumor on scans (not just bone lesions)
- Your blood counts, kidney function, and liver function are adequate for chemotherapy
- You are willing to use effective birth control for at least 2–6 months after treatment ends if you can become pregnant
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests new treatment combinations for colorectal cancer that has spread (metastatic). It is for people whose cancer is mismatch repair proficient (pMMR) or microsatellite stable (MSS) and who have not had previous treatment for metastatic disease.
This trial tests a new drug combination for people with colorectal cancer that has spread and cannot be removed by surgery. It compares the new drug plus standard chemotherapy against a placebo plus the same chemotherapy, to see if it helps shrink tumors and slow the disease.
This trial tests a new drug combined with standard chemotherapy and another medication for people with advanced colorectal cancer that has a specific genetic change (RAS mutation). It aims to see if the combination can help control the cancer better.
This trial tests a combination of three drugs (irinotecan liposomes, cetuximab, and vemurafenib) for people with advanced colorectal cancer that has a specific genetic change (BRAF V600E mutation) and did not respond to first treatment. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This trial tests a new drug designed to slow or stop the growth of advanced colorectal cancer that has spread and can't be removed with surgery. It may be an option if standard treatments have stopped working or aren't suitable for you.
This trial tests a combination of two drugs, regorafenib and 5-FU with leucovorin, for people with colorectal cancer that has spread and has not responded to at least two previous treatments. The goal is to see if this new mix can help shrink or control the cancer.
Hear when a new Metastatic Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.